ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!
ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!On January 28, 2022, the FDA approved the first bispecific antibody Vabysmo (Ang-2 x VEGF-A) for eye, to treat two leading causes of vision loss--wet age-related macular degeneration (AMD) and diabetic macular edema (DME...
Detailed information

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)The first GPRC5D CAR-T study from China (Identifier: NCT05219721), updated on ClinicalTrials.gov website (Feb. 2, 2022), has become a hot topic these days. The Phase I Trial of GPRC5D CAR-T started in Feb. 8, 2022, has b...
Detailed information

CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!
CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!BioLineRx Ltd presently has completed a successful pre-New Drug Application (NDA) meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide), from a report on January 18, 2022. In particular, the biopharmace...
Detailed information

The Collection of Progress of Anti-GPCR Antibody Drugs
The Collection of Progress of Anti-GPCR Antibody DrugsAs mentioned in the article entitled "G protein-Coupled Receptor - Targets for Drug Therapy", GPCRs is an important drug target, and currently about 40% of the marketed drugs are designed based on GPCRs. About 34% of dru...
Detailed information

Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer Immunotherapy
Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer ImmunotherapyOn Jan 17, 2022, Nature Reviews Clinical Oncology (IF: 66.675) published a review entitled "Harnessing cytokines and chemokines for cancer therapy" [1]. In this article, the authors conclude the high potential of targeti...
Detailed information

IGFL1: A Novel Secretory Protein of IGF-Like Family Presents a High Cancer-Promoting Potential!
IGFL1: A Novel Secretory Protein of IGF-Like Family Presents a High Cancer-Promoting Potential!Cancer Letters presently published a paper entitled "KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1" [1]. The study suggested that IGFL1 a...
Detailed information

The Review of Post-translational Modifications
The Review of Post-translational ModificationsThe human genome comprises between 20,000 and 25,000 protein-encoding genes [1], while the human proteome is estimated at up to 1,000,000 proteins [2]. Why is the human proteome size far larger than the human gene set? I...
Detailed information

Bispecific Antibody Overview: From Definition to Application
Bispecific Antibody Overview: From Definition to Application2022 seems to be a "blowout" year in the field of bispecific antibody research and development. The number of drugs on the market in less than one year will exceed the sum of the number of bispecific antibody drugs on th...
Detailed information

CD24: A New Treatment EXO-CD24 via
CD24: A New Treatment EXO-CD24 via "Tiny Carriers" Exosomes to Resist COVID-19?On July 18, 2021, the WHO COVID-19 Database updated Israel's phase II clinical data on EXO-CD24, a new treatment for COVID-19 (Click here to read more). The preliminary results uncovered that the 29 out of 30 patients wi...
Detailed information

Cellular Senescence and Its Markers
Cellular Senescence and Its MarkersA cell is not only the basic unit of biological structure and function but also of organismal aging. Most cells of an organism go through several stages during their lives: proliferation, differentiation, senescence, and...
Detailed information

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1